MPM
FLGT icon

Meritage Portfolio Management’s Fulgent Genetics FLGT Stock Holding History

Meritage Portfolio Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,080
Closed -$213K – 289
2020
Q4 		$213K Buy
+4,080
New +$170K 0.02% 247

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Meritage Portfolio Management's FLGT Position: Q1 2021 in Review

Meritage Portfolio Management sold out of Fulgent Genetics (FLGT) in Q1 2021, closing a stake of 4,080 shares — an estimated $213K sold.

Meritage Portfolio Management first reported a position in FLGT in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 256 funds tracked by Wall St. Rank hold FLGT as of Q1 2021.

  • Meritage Portfolio Management reported no remaining Fulgent Genetics position as of Q1 2021 after selling out during the quarter.
  • Meritage Portfolio Management sold 4,080 Fulgent Genetics shares in Q1 2021, an estimated $213K.
  • Meritage Portfolio Management first reported a position in Fulgent Genetics in Q4 2020 and held it in 1 quarter.
  • Meritage Portfolio Management's Fulgent Genetics position peaked at $213K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2021.

Based on Meritage Portfolio Management's 13F filing for Q1 2021, filed 27 Apr 2021.